Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology

This publication has 55 references indexed in Scilit:

• A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil®/Aerolizer™) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients
  Respiration, 2005
• A Randomized, Double-Blind, Double-Dummy, Single-Dose, Efficacy Crossover Trial Comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (AerolizerTM) and Placebo (pMDI or AerolizerTM) in Asthmatic Patients
  Respiration, 2005
• A Randomized, Double-Blind, Double-Dummy, Safety Crossover Trial Comparing Cumulative Doses up to 96 μg of Formoterol Delivered via an HFA-134a-Propelled pMDI vs. Same Cumulative Doses of Formoterol DPI and Placebo in Asthmatic Patients
  Respiration, 2005
• Double-Blind, Double-Dummy, Multinational, Multicenter, Parallel-Group Design Clinical Trial of Clinical Non-Inferiority of Formoterol 12 μg/Unit Dose in a b.i.d. Regimen Administered via an HFA-Propellant-pMDI or a Dry Powder Inhaler in a 12-Week Treatment Period of Moderate to Severe Stable Persistent Asthma in Adult Patients
  Respiration, 2005
• Imaging Drug Delivery and Drug Responses in the Lung
  Proceedings of the American Thoracic Society, 2004
• Combination therapy with maintenance budesonide and formoterol in COPD
  European Respiratory Journal, 2004
• Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease
  Published by Wiley ,2004
• Deposition of Foradil P in Human Lungs: Comparison ofIn VitroandIn VivoData
  Journal of Aerosol Medicine, 2004
• Budesonide/Formoterol
  Drugs, 2004
• Assessment of Efficacy and Systemic Safety of a New Chlorofluorocarbon-Free Formulation of Inhaled Beclomethasone Dipropionate in Asthmatic Children
  Pediatric Asthma, Allergy & Immunology, 2002